Abstract
Abstract: :
Purpose: Dominant Cystoid Macula Dystrophy (DCMD) is an autosomal dominant retinal dystrophy defined by leaking capillaries; especially perimacularly. Since somatostatine analogues like octreotide have a suggested positive effect in macular edema, we hypothesized that somatostatin could also have an positive effect on the early stages of DCMD. Methods: In this prospective study fluoresceine angiography (FAG) and vision acuity were assessed of 10 proven DCMD patients. OCT was performed in 2 patients and ERG/EOG in 3 patients. Each patient received 10 mg somatostatin IM once every six weeks. After 4 and 8 months we repeated the FAG, the vision examination and we measured eventual subjective decline or improvement. Results: At 8 months after treatment, all patients showed clear remission of the the edema on the FAG and on the OCT. 1 Patient showed significant improvement of vision, the other 9 did not show any significant changes. 8 Patients claimed subjective improvement, 2 patients did not experience any visual changes. Conclusions: The results show clear remission of the edema in DCMD, though there is no significant vision improvement. This study shows that somatostatin has a positive effect in the pathogenesis of DCMD, but more research needs to be done to analyse if vision decrease can be stabilized in the long run of the disease.
Keywords: macula/fovea • drug toxicity/drug effects